NCT05749016 2023-03-01Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Unknown30 enrolled